Lilly to End Development of Lupus Drug on Trial Failure

October 2, 2014 1:16 PM

17 0

Eli Lilly & Co. (LLY:US) will end development of an experimental drug for lupus after the medicine failed to help patients in two late-stage clinical trials.

The treatment, tabalumab, didn’t produce a statistically significant improvement for patients taking either of two doses in the Illuminate 1 study, the Indianapolis-based company said in a statement today. In another trial, dubbed Illuminate 2, the higher dose did meet the goal of the trial, but col...

Read more

To category page